Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study
单位：[1]Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China[2]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[3]Sichuan Univ, West China Hosp, Stat Key Lab Biotherapy & Canc Ctr, Lab Mol Diag Canc, Chengdu, Peoples R China四川大学华西医院[4]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[5]Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China[6]Henan Canc Hosp, Breast Dis Ctr, Zhengzhou, Peoples R China河南省肿瘤医院[7]Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[8]Sun Yat Gen Univ, Canc Ctr, Guangdong, Peoples R China[9]Guangdong Acad Med Sci, Guangzhou, Peoples R China广东省人民医院[10]Guangdong Gen Hosp, Guangzhou, Peoples R China广东省人民医院[11]Southern Med Univ, Ctr Canc, Guangzhou, Peoples R China[12]Peking Union Med Coll Hosp, Beijing, Peoples R China[13]Tongji Hosp, Oncol Ctr, Wuhan, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院
Xu Binghe,Hu Xi-Chun,Zheng Hong,et al.Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study[J].JOURNAL OF CLINICAL ONCOLOGY.2016,34(15):doi:10.1200/JCO.2016.34.15_suppl.e12068.
APA：
Xu, Binghe,Hu, Xi-Chun,Zheng, Hong,Wang, Xiaojia,Zhang, Qingyuan...&Yu, Shiying.(2016).Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study.JOURNAL OF CLINICAL ONCOLOGY,34,(15)
MLA：
Xu, Binghe,et al."Outcomes of re-treatment with first-line trastuzumab plus taxane in patients (pts) with metastatic breast cancer (mBC) who relapsed after (neo)adjuvant trastuzumab: A prospective multicenter study".JOURNAL OF CLINICAL ONCOLOGY 34..15(2016)
医学